136 related articles for article (PubMed ID: 37232154)
1. Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer.
Catalano M; Roviello G; Aprile G; Ramello M; Conca R; Petrioli R; Perrone G; Ianza A; Mini E
Future Oncol; 2023 Apr; 19(13):937-946. PubMed ID: 37232154
[TBL] [Abstract][Full Text] [Related]
2. A comparison of gamma-glutamyl transferase and alkaline phosphatase as prognostic markers in patients with coronary heart disease.
Ndrepepa G; Holdenrieder S; Cassese S; Fusaro M; Xhepa E; Laugwitz KL; Schunkert H; Kastrati A
Nutr Metab Cardiovasc Dis; 2018 Jan; 28(1):64-70. PubMed ID: 29126670
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resection.
Wu SJ; Lin YX; Ye H; Xiong XZ; Li FY; Cheng NS
Int J Surg; 2016 Dec; 36(Pt A):143-151. PubMed ID: 27793641
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
[TBL] [Abstract][Full Text] [Related]
5. High levels of both serum gamma-glutamyl transferase and alkaline phosphatase are independent preictors of mortality in patients with stage 4-5 chronic kidney disease.
Caravaca-Fontán F; Azevedo L; Bayo MÁ; Gonzales-Candia B; Luna E; Caravaca F
Nefrologia; 2017; 37(3):267-275. PubMed ID: 28648203
[TBL] [Abstract][Full Text] [Related]
6. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
8. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
9. Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis.
Xu XS; Wan Y; Song SD; Chen W; Miao RC; Zhou YY; Zhang LQ; Qu K; Liu SN; Zhang YL; Dong YF; Liu C
World J Gastroenterol; 2014 Aug; 20(31):10944-52. PubMed ID: 25152598
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Yang L; Su J; Wang W; Zhou F
World J Surg Oncol; 2023 Jan; 21(1):19. PubMed ID: 36691032
[TBL] [Abstract][Full Text] [Related]
11. A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study.
Chang C; Meng L; Li X; Cheng K; Yi C; Peng B; Ma J; Cao D
Cancer Control; 2022; 29():10732748221141233. PubMed ID: 36423238
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S
Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients.
Ishimoto U; Kinoshita A; Hirose Y; Shibata K; Ishii A; Shoji R; Yokota T; Iwaku A; Mizuno Y; Koike K; Saruta M
Cancer Chemother Pharmacol; 2019 Sep; 84(3):647-654. PubMed ID: 31230157
[TBL] [Abstract][Full Text] [Related]
14. Model Based on Alkaline Phosphatase and Gamma-Glutamyltransferase for Gallbladder Cancer Prognosis.
Xu XS; Miao RC; Zhang LQ; Wang RT; Qu K; Pang Q; Liu C
Asian Pac J Cancer Prev; 2015; 16(15):6255-9. PubMed ID: 26434825
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Tabernero J; Chiorean EG; Infante JR; Hingorani SR; Ganju V; Weekes C; Scheithauer W; Ramanathan RK; Goldstein D; Penenberg DN; Romano A; Ferrara S; Von Hoff DD
Oncologist; 2015 Feb; 20(2):143-50. PubMed ID: 25582141
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence.
Prejac J; Tomek Hamzić D; Librenjak N; Goršić I; Kekez D; Pleština S
Medicine (Baltimore); 2022 Sep; 101(39):e30566. PubMed ID: 36181099
[TBL] [Abstract][Full Text] [Related]
18. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
20. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
